Skip to main content
GenMont logo

GenMont — Investor Relations & Filings

Ticker · 3164 ISIN · TW0003164000 TW Manufacturing
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2014-09-18 Capital/Financing Update
Country TW Taiwan
Listing TW 3164

About GenMont

www.genmont.com.tw

GenMont Biotech Inc. specializes in the research, development, and manufacturing of functional probiotics and postbiotics. The company operates advanced fermentation and production platforms for concentrated fermented milk, lactic acid bacteria powders, and functional microorganism strains. Its product portfolio features patented probiotic solutions targeting diverse health areas, including immune modulation, metabolic health, dental hygiene, digestive function, weight management, and pet wellness. Key proprietary strains include L. paracasei 33 and GMNL-32. GenMont leverages its technology platforms and extensive patent portfolio to deliver scientifically-backed health supplements. Beyond its proprietary brands, the company provides original equipment manufacturing (OEM) services, supporting the global market with high-quality probiotic and postbiotic ingredients certified by international standards.

Recent filings

Filing Released Lang Actions
103年9月公開說明書 — 201405_3164_B012.pdf
Capital/Financing Update Classification · 95% confidence The document is titled as a "公開說明書" (Public Offering Prospectus) for a cash capital increase and issuance of new shares by GenMont Biotech Inc. It details the issuance of new shares, the capital structure, underwriting, use of proceeds, and related legal and financial information. The document includes extensive company background, risk factors, organizational structure, capital and shares information, and financial data. This type of document is a detailed disclosure related to capital raising activities, specifically a public offering or capital increase. It is not a general annual report, earnings release, or management discussion. It is a formal disclosure document for a capital/financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail confirm it is the actual disclosure, not just an announcement or summary.
2014-09-18 Chinese
103年9月公開說明書 — 201405_3164_B011.zip
Regulatory Filings
2014-09-18 Chinese
103年9月公開說明書 — 201208_3164_B04.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed "公開說明書" (Public Offering Prospectus) for a company named 景岳生物科技股份有限公司 (GenMont Biotech Inc.) related to a merger and capital increase through issuance of new shares. It includes extensive information about the company, capital structure, merger details, issuance conditions, financial data, legal and accounting certifications, and other disclosures typical of a prospectus for a capital raising event. The document is not a simple announcement but a comprehensive disclosure document prepared for regulatory and investor information purposes. This fits the definition of a Capital/Financing Update (CAP) as it relates to fundraising and capital structure changes through a merger and new share issuance. It is not an Annual Report, Audit Report, or other categories related to earnings, governance, or legal proceedings. The length and detail confirm it is the actual disclosure document, not just an announcement or summary. Therefore, the correct classification is CAP with high confidence.
2014-09-18 Chinese
103年9月公開說明書 — 201208_3164_B011.zip
Regulatory Filings
2014-09-18 Chinese
103年9月公開說明書 — 201012_3164_B05.pdf
Regulatory Filings
2014-09-18 Chinese
103年9月公開說明書 — 201011_3164_B022.zip
Regulatory Filings
2014-09-18 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.